Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 2011

View Archived Issues

Alzheimer's Drug Discovery Foundation awards drug development grant to Madera Biosciences

New biomarker described of mortality and hospitalization due to chronic heart failure

Findings from phase IV ESSENCE-DIABETES study disclosed

New neuraminidase inhibitors presented by Canadian university

Novel antibacterial agents synthesized by KBP Biosciences

Nerviano Medical Sciences discloses new B-raf inhibitors

NicOx reports novel agents for neuropathic pain

Boehringer Ingelheim presents novel HCV NS5A inhibitors

New corticotropin-releasing factor CRF1 receptor antagonists claimed

Bivalent HPV-16/18 vaccine shows potential against anal HPV infection

Study identifies new SNPs linked to risk of prostate cancer-specific mortality

Extended-release tapentadol receives FDA approval for chronic pain

Boehringer Ingelheim to launch new phase II trial of dabigatran etexilate

Abbott and Eisai to launch pancreatic digestive enzyme replacement products in Japan

Astellas Pharma applies for approvals of mirabegron in U.S. and Europe

Afexa Life Sciences reports encouraging results from pediatric clinical trial of COLD-FX

Phase III trial compares Ferinject and Venofer in IBD-associated iron deficiency anemia

Actelion reports results from MUSIC trial of macitentan

Takeda initiates two phase II trials of TAK-385 in Japan

Mologen reports results from phase I/II renal cancer trial

PAION initiates phase Ib study of Solulin

Novartis receives complete response letter from FDA regarding canakinumab

Cellestis acquired by QIAGEN

Berinert for self-administration approved in Europe

FDA approves Xalkori and companion diagnostic kit

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...